Trial Outcomes & Findings for Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat (NCT NCT02935894)
NCT ID: NCT02935894
Last Updated: 2018-06-01
Results Overview
Approximately 150 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids and endocannabinoid-like molecules, and sphingolipids.
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
14 participants
Primary outcome timeframe
measured at study visit 1, 2 and 3; detected lipid mediator concentrations for study visit 1 reported
Results posted on
2018-06-01
Participant Flow
Participant milestones
| Measure |
Single Group
Subjects will participate in 4 study visits in the same order.
1. compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological induction of sweating (exercise using a stationary bicycle).
2. compare sweat collected following stimulation of sweating by pilocarpine from the inner part of the forearm (near the wrist) to upper surface of thigh (near the knee).
3. collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist).
4. collect blood and sweat samples before and 30 minutes, 2 hours and 4 hours after consumption of 400 mg of ibuprofen.
Ibuprofen: 400 mg ibuprofen given to inhibit cyclooxygenase metabolism
Physiological induction of sweating: 15 minutes exercise at 60-80% oxygen consumption to induce sweating
Pilocarpine: Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine
|
|---|---|
|
Overall Study
STARTED
|
14
|
|
Overall Study
COMPLETED
|
13
|
|
Overall Study
NOT COMPLETED
|
1
|
Reasons for withdrawal
| Measure |
Single Group
Subjects will participate in 4 study visits in the same order.
1. compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological induction of sweating (exercise using a stationary bicycle).
2. compare sweat collected following stimulation of sweating by pilocarpine from the inner part of the forearm (near the wrist) to upper surface of thigh (near the knee).
3. collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist).
4. collect blood and sweat samples before and 30 minutes, 2 hours and 4 hours after consumption of 400 mg of ibuprofen.
Ibuprofen: 400 mg ibuprofen given to inhibit cyclooxygenase metabolism
Physiological induction of sweating: 15 minutes exercise at 60-80% oxygen consumption to induce sweating
Pilocarpine: Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine
|
|---|---|
|
Overall Study
Subject dismissed
|
1
|
Baseline Characteristics
Race and Ethnicity were not collected from any participant.
Baseline characteristics by cohort
| Measure |
Single Group
n=14 Participants
All subjects will participate in 4 study day visits in the same order.
1. compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological induction of sweating (exercise on a stationary bicycle).
2. compare sweat collected following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) to upper surface of thigh (near the knee).
3. collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist).
4. collect blood and sweat samples before and 30 minutes, 2 hours and 4 hours after consumption of 400 mg of ibuprofen.
Ibuprofen: 400 mg ibuprofen given to inhibit cyclooxygenase (COX) metabolism
Physiological induction of sweating: 15 minutes exercise at 60-80% oxygen consumption to induce sweating
Pilocarpine: Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a
|
|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=14 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
14 Participants
n=14 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=14 Participants
|
|
Sex: Female, Male
Female
|
0 Participants
n=14 Participants
|
|
Sex: Female, Male
Male
|
14 Participants
n=14 Participants
|
|
Region of Enrollment
United States
|
14 participants
n=14 Participants
|
|
Height
|
179.2 centimeters
STANDARD_DEVIATION 6.2 • n=14 Participants
|
|
Weight
|
82.6 kilograms
STANDARD_DEVIATION 15.9 • n=14 Participants
|
|
Body Mass Index
|
25.8 kilograms per square meter
STANDARD_DEVIATION 5.0 • n=14 Participants
|
|
Perceived Exercise Intensity
|
1.6 units on a scale
STANDARD_DEVIATION 0.5 • n=14 Participants
|
PRIMARY outcome
Timeframe: measured at study visit 1, 2 and 3; detected lipid mediator concentrations for study visit 1 reportedPopulation: Of the 14 subjects recruited for this study, only 7 provided usable data for this primary outcome.
Approximately 150 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids and endocannabinoid-like molecules, and sphingolipids.
Outcome measures
| Measure |
Single Group
n=7 Participants
All subjects will participate in 4 study day visits in the same order.
1. compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological induction of sweating (exercise using a stationary bicycle).
2. compare sweat collected following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) to upper surface of thigh (near the knee).
3. collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist).
4. collect blood and sweat samples before and 30 minutes, 2 hours and 4 hours after consumption of 400 mg of ibuprofen.
Ibuprofen: 400 mg ibuprofen given to inhibit COX metabolism
Physiological induction of sweating: 15 minutes exercise at 60-80% oxygen consumption to induce sweating
Pilocarpine: Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine
|
|---|---|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
C24 Ceramide
|
5.7 picomoles per milliliter
Standard Deviation 4.9
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
18:1 Sphingosine
|
15 picomoles per milliliter
Standard Deviation 8.9
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
13-HODE
|
46 picomoles per milliliter
Standard Deviation 28
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9-HOTrE
|
2.2 picomoles per milliliter
Standard Deviation 1.2
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
12,13-DiHOME
|
3.4 picomoles per milliliter
Standard Deviation 2.3
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
11,12-DiHETrE
|
0.51 picomoles per milliliter
Standard Deviation 0.29
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
10-Nitrolinoleate
|
0.11 picomoles per milliliter
Standard Deviation 0.069
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
PGE1
|
0.24 picomoles per milliliter
Standard Deviation 0.15
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
PGE2
|
2.1 picomoles per milliliter
Standard Deviation 1.8
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
PEA
|
7.9 picomoles per milliliter
Standard Deviation 6.8
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
NO-Gly
|
0.48 picomoles per milliliter
Standard Deviation 0.22
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
NA-Gly
|
0.017 picomoles per milliliter
Standard Deviation 0.02
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
C14 Ceramide
|
1.4 picomoles per milliliter
Standard Deviation 1.1
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
C16 Ceramide
|
6.6 picomoles per milliliter
Standard Deviation 4.7
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
C18 Ceramide
|
1.2 picomoles per milliliter
Standard Deviation 0.66
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9-HODE
|
20 picomoles per milliliter
Standard Deviation 9.8
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
13-HOTrE
|
3.5 picomoles per milliliter
Standard Deviation 1.8
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
5-HETE
|
0.1 picomoles per milliliter
Standard Deviation 0.07
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
8-HETE
|
0.23 picomoles per milliliter
Standard Deviation 0.062
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9-HETE
|
0.12 picomoles per milliliter
Standard Deviation 0.062
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
11-HETE
|
0.15 picomoles per milliliter
Standard Deviation 0.055
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
12-HETE
|
0.85 picomoles per milliliter
Standard Deviation 0.94
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
15-HETE
|
0.43 picomoles per milliliter
Standard Deviation 0.25
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
12-HEPE
|
0.086 picomoles per milliliter
Standard Deviation 0.044
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9,10-e-DiHO
|
85 picomoles per milliliter
Standard Deviation 37
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9,10-DiHOME
|
4.4 picomoles per milliliter
Standard Deviation 3
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9,10-DiHODE
|
0.85 picomoles per milliliter
Standard Deviation 1.1
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
12,13-DiHODE
|
0.5 picomoles per milliliter
Standard Deviation 0.31
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
15,16-DiHODE
|
2.7 picomoles per milliliter
Standard Deviation 3.9
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
5,6-DiHETrE
|
5.3 picomoles per milliliter
Standard Deviation 2.5
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
8,9-DiHETrE
|
0.73 picomoles per milliliter
Standard Deviation 0.43
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
14,15-DiHETrE
|
0.65 picomoles per milliliter
Standard Deviation 0.4
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9,10-EpOME
|
1.7 picomoles per milliliter
Standard Deviation 0.79
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
12,13-EpOME
|
0.96 picomoles per milliliter
Standard Deviation 0.29
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9,10-EpODE
|
0.55 picomoles per milliliter
Standard Deviation 0.54
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
12,13-EpODE
|
0.12 picomoles per milliliter
Standard Deviation 0.066
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
15,16-EpODE
|
3.5 picomoles per milliliter
Standard Deviation 3.4
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9-KODE
|
14 picomoles per milliliter
Standard Deviation 6.3
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
13-KODE
|
7.2 picomoles per milliliter
Standard Deviation 3.8
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
12,13-Ep-9-KODE
|
3.7 picomoles per milliliter
Standard Deviation 2.8
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
5-KETE
|
0.025 picomoles per milliliter
Standard Deviation 0.019
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
LTB5
|
0.1 picomoles per milliliter
Standard Deviation 0.094
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
10-Nitrooleate
|
0.096 picomoles per milliliter
Standard Deviation 0.054
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
PGF2a
|
0.14 picomoles per milliliter
Standard Deviation 0.14
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
15-deoxy PGJ2
|
0.033 picomoles per milliliter
Standard Deviation 0.012
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
PGE3
|
0.13 picomoles per milliliter
Standard Deviation 0.17
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
Sum TriHOMEs
|
57 picomoles per milliliter
Standard Deviation 56
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
SEA
|
7.9 picomoles per milliliter
Standard Deviation 6.7
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
OEA
|
0.32 picomoles per milliliter
Standard Deviation 0.38
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
LEA
|
0.043 picomoles per milliliter
Standard Deviation 0.035
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
aLEA
|
0.0047 picomoles per milliliter
Standard Deviation 0.0036
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
Dihomo GLA EA
|
0.0022 picomoles per milliliter
Standard Deviation 0.003
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
AEA
|
0.019 picomoles per milliliter
Standard Deviation 0.011
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
DEA
|
0.17 picomoles per milliliter
Standard Deviation 0.24
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
1-OG
|
870 picomoles per milliliter
Standard Deviation 1300
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
2-OG
|
190 picomoles per milliliter
Standard Deviation 270
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
1-LG
|
300 picomoles per milliliter
Standard Deviation 540
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
2-LG
|
2.3 picomoles per milliliter
Standard Deviation 1.1
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
1-AG
|
14 picomoles per milliliter
Standard Deviation 12
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
2-AG
|
15 picomoles per milliliter
Standard Deviation 30
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
C20 Ceramide
|
2 picomoles per milliliter
Standard Deviation 1.4
|
PRIMARY outcome
Timeframe: measured at study visit 1, detected lipid mediator concentrations reportedPopulation: Of the 14 subjects recruited for this study, only 7 provided usable data for this primary outcome.
Approximately 150 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids and endocannabinoid-like molecules, and sphingolipids.
Outcome measures
| Measure |
Single Group
n=7 Participants
All subjects will participate in 4 study day visits in the same order.
1. compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological induction of sweating (exercise using a stationary bicycle).
2. compare sweat collected following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) to upper surface of thigh (near the knee).
3. collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist).
4. collect blood and sweat samples before and 30 minutes, 2 hours and 4 hours after consumption of 400 mg of ibuprofen.
Ibuprofen: 400 mg ibuprofen given to inhibit COX metabolism
Physiological induction of sweating: 15 minutes exercise at 60-80% oxygen consumption to induce sweating
Pilocarpine: Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine
|
|---|---|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
9-HETE
|
0.029 picomoles per milliliter
Standard Deviation 0.018
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
11-HETE
|
0.012 picomoles per milliliter
Standard Deviation 0.0061
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
12-HETE
|
0.04 picomoles per milliliter
Standard Deviation 0.031
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
15-HETE
|
0.074 picomoles per milliliter
Standard Deviation 0.054
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
12-HEPE
|
0.029 picomoles per milliliter
Standard Deviation 0.015
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
9,10-e-DiHO
|
21 picomoles per milliliter
Standard Deviation 12
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
9,10-DiHOME
|
3.1 picomoles per milliliter
Standard Deviation 1.8
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
12,13-DiHOME
|
2.8 picomoles per milliliter
Standard Deviation 1.6
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
9,10-DiHODE
|
0.56 picomoles per milliliter
Standard Deviation 0.68
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
12,13-DiHODE
|
0.3 picomoles per milliliter
Standard Deviation 0.12
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
15,16-DiHODE
|
1.9 picomoles per milliliter
Standard Deviation 2.3
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
5,6-DiHETrE
|
0.026 picomoles per milliliter
Standard Deviation 0.037
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
8,9-DiHETrE
|
0.24 picomoles per milliliter
Standard Deviation 0.25
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
11,12-DiHETrE
|
0.022 picomoles per milliliter
Standard Deviation 0.026
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
14,15-DiHETrE
|
0.041 picomoles per milliliter
Standard Deviation 0.018
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
9,10-EpOME
|
0.46 picomoles per milliliter
Standard Deviation 0.31
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
12,13-EpOME
|
0.36 picomoles per milliliter
Standard Deviation 0.22
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
9,10-EpODE
|
0.19 picomoles per milliliter
Standard Deviation 0.18
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
12,13-EpODE
|
0.019 picomoles per milliliter
Standard Deviation 0.014
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
15,16-EpODE
|
0.82 picomoles per milliliter
Standard Deviation 0.86
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
9-KODE
|
1.5 picomoles per milliliter
Standard Deviation 1.4
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
13-KODE
|
0.89 picomoles per milliliter
Standard Deviation 0.6
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
12,13-Ep-9-KODE
|
3.4 picomoles per milliliter
Standard Deviation 1.8
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
5-KETE
|
0.02 picomoles per milliliter
Standard Deviation 0.017
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
LTB5
|
0.099 picomoles per milliliter
Standard Deviation 0.082
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
10-Nitrooleate
|
0.074 picomoles per milliliter
Standard Deviation 0.043
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
10-Nitrolinoleate
|
0.087 picomoles per milliliter
Standard Deviation 0.078
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
PGE1
|
0.85 picomoles per milliliter
Standard Deviation 1
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
PGE2
|
1.1 picomoles per milliliter
Standard Deviation 1.3
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
PGF2a
|
0.44 picomoles per milliliter
Standard Deviation 0.74
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
15-deoxy PGJ2
|
0.046 picomoles per milliliter
Standard Deviation 0.036
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
PGE3
|
0.18 picomoles per milliliter
Standard Deviation 0.21
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
Sum TriHOMEs
|
130 picomoles per milliliter
Standard Deviation 130
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
PEA
|
14 picomoles per milliliter
Standard Deviation 25
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
9-HODE
|
2.4 picomoles per milliliter
Standard Deviation 1.9
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
13-HODE
|
5.2 picomoles per milliliter
Standard Deviation 3.9
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
9-HOTrE
|
0.6 picomoles per milliliter
Standard Deviation 0.5
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
13-HOTrE
|
1.5 picomoles per milliliter
Standard Deviation 1.4
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
5-HETE
|
0.023 picomoles per milliliter
Standard Deviation 0.018
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
8-HETE
|
0.14 picomoles per milliliter
Standard Deviation 0.061
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
OEA
|
0.11 picomoles per milliliter
Standard Deviation 0.093
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
LEA
|
0.019 picomoles per milliliter
Standard Deviation 0.01
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
aLEA
|
0.0033 picomoles per milliliter
Standard Deviation 0.0024
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
SEA
|
15 picomoles per milliliter
Standard Deviation 25
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
Dihomo GLA EA
|
0.0023 picomoles per milliliter
Standard Deviation 0.0036
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
AEA
|
0.017 picomoles per milliliter
Standard Deviation 0.025
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
DEA
|
0.015 picomoles per milliliter
Standard Deviation 0.013
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
1-OG
|
11 picomoles per milliliter
Standard Deviation 14
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
2-OG
|
7 picomoles per milliliter
Standard Deviation 7.3
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
1-LG
|
2.1 picomoles per milliliter
Standard Deviation 1.8
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
2-LG
|
0.34 picomoles per milliliter
Standard Deviation 0.36
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
1-AG
|
1.8 picomoles per milliliter
Standard Deviation 3.1
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
2-AG
|
0.79 picomoles per milliliter
Standard Deviation 1
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
NO-Gly
|
0.15 picomoles per milliliter
Standard Deviation 0.13
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
NA-Gly
|
0.01 picomoles per milliliter
Standard Deviation 0.012
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
C14 Ceramide
|
0.23 picomoles per milliliter
Standard Deviation 0.18
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
C16 Ceramide
|
1 picomoles per milliliter
Standard Deviation 1
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
C18 Ceramide
|
0.29 picomoles per milliliter
Standard Deviation 0.34
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
C20 Ceramide
|
0.36 picomoles per milliliter
Standard Deviation 0.34
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
C24 Ceramide
|
0.88 picomoles per milliliter
Standard Deviation 0.8
|
|
Volar Forearm Sweat Lipid Mediator Concentrations Following Exercise
18:1 Sphingosine
|
4.9 picomoles per milliliter
Standard Deviation 4.6
|
PRIMARY outcome
Timeframe: measured at study visit 1, detected lipid mediator concentrations reportedPopulation: Of the 14 subjects recruited for this study, only 4 provided usable data for this primary outcome.
Approximately 150 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids and endocannabinoid-like molecules, and sphingolipids.
Outcome measures
| Measure |
Single Group
n=4 Participants
All subjects will participate in 4 study day visits in the same order.
1. compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological induction of sweating (exercise using a stationary bicycle).
2. compare sweat collected following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) to upper surface of thigh (near the knee).
3. collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist).
4. collect blood and sweat samples before and 30 minutes, 2 hours and 4 hours after consumption of 400 mg of ibuprofen.
Ibuprofen: 400 mg ibuprofen given to inhibit COX metabolism
Physiological induction of sweating: 15 minutes exercise at 60-80% oxygen consumption to induce sweating
Pilocarpine: Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine
|
|---|---|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
5,6-DiHETrE
|
2.8 picomoles per milliliter
Standard Deviation 1.8
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
8,9-DiHETrE
|
0.1 picomoles per milliliter
Standard Deviation 0.22
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9-HODE
|
17 picomoles per milliliter
Standard Deviation 11
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
13-HODE
|
81 picomoles per milliliter
Standard Deviation 42
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9-HOTrE
|
1.8 picomoles per milliliter
Standard Deviation 0.65
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
13-HOTrE
|
2.6 picomoles per milliliter
Standard Deviation 1.1
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
5-HETE
|
0.15 picomoles per milliliter
Standard Deviation 0.1
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
8-HETE
|
0.23 picomoles per milliliter
Standard Deviation 0.21
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9-HETE
|
0.12 picomoles per milliliter
Standard Deviation 0.083
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
11-HETE
|
0.2 picomoles per milliliter
Standard Deviation 0.27
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
12-HETE
|
0.3 picomoles per milliliter
Standard Deviation 0.22
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
15-HETE
|
0.32 picomoles per milliliter
Standard Deviation 0.2
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
12-HEPE
|
0.15 picomoles per milliliter
Standard Deviation 0.11
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9,10-e-DiHO
|
36 picomoles per milliliter
Standard Deviation 13
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9,10-DiHOME
|
2.6 picomoles per milliliter
Standard Deviation 0.73
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
12,13-DiHOME
|
2.2 picomoles per milliliter
Standard Deviation 0.52
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9,10-DiHODE
|
0.38 picomoles per milliliter
Standard Deviation 0.16
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
12,13-DiHODE
|
0.34 picomoles per milliliter
Standard Deviation 0.14
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
15,16-DiHODE
|
0.55 picomoles per milliliter
Standard Deviation 0.16
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
11,12-DiHETrE
|
0.28 picomoles per milliliter
Standard Deviation 0.039
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
14,15-DiHETrE
|
0.34 picomoles per milliliter
Standard Deviation 0.067
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9,10-EpOME
|
1.6 picomoles per milliliter
Standard Deviation 1.1
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
12,13-EpOME
|
1.6 picomoles per milliliter
Standard Deviation 1.3
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9,10-EpODE
|
0.28 picomoles per milliliter
Standard Deviation 0.15
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
12,13-EpODE
|
0.2 picomoles per milliliter
Standard Deviation 0.1
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
15,16-EpODE
|
0.49 picomoles per milliliter
Standard Deviation 0.34
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9-KODE
|
11 picomoles per milliliter
Standard Deviation 9.2
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
13-KODE
|
6 picomoles per milliliter
Standard Deviation 2.9
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
12,13-Ep-9-KODE
|
2.6 picomoles per milliliter
Standard Deviation 0.94
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
5-KETE
|
0.1 picomoles per milliliter
Standard Deviation 0.12
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
LTB5
|
0.13 picomoles per milliliter
Standard Deviation 0.093
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
10-Nitrooleate
|
0.75 picomoles per milliliter
Standard Deviation 1.2
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
10-Nitrolinoleate
|
0.26 picomoles per milliliter
Standard Deviation 0.31
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
PGE1
|
0.11 picomoles per milliliter
Standard Deviation 0.046
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
PGE2
|
0.62 picomoles per milliliter
Standard Deviation 0.28
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
PGF2a
|
0.27 picomoles per milliliter
Standard Deviation 0.15
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
PGE3
|
0.17 picomoles per milliliter
Standard Deviation 0.13
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
Sum TriHOMEs
|
12 picomoles per milliliter
Standard Deviation 11
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
PEA
|
47 picomoles per milliliter
Standard Deviation 65
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
SEA
|
53 picomoles per milliliter
Standard Deviation 73
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
OEA
|
0.55 picomoles per milliliter
Standard Deviation 0.46
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
LEA
|
0.14 picomoles per milliliter
Standard Deviation 0.14
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
aLEA
|
0.11 picomoles per milliliter
Standard Deviation 0.14
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
Dihomo GLA EA
|
0.05 picomoles per milliliter
Standard Deviation 0.083
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
AEA
|
0.14 picomoles per milliliter
Standard Deviation 0.19
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
DEA
|
0.028 picomoles per milliliter
Standard Deviation 0.069
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
1-OG
|
300 picomoles per milliliter
Standard Deviation 210
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
2-OG
|
46 picomoles per milliliter
Standard Deviation 47
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
1-LG
|
110 picomoles per milliliter
Standard Deviation 82
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
2-LG
|
2.6 picomoles per milliliter
Standard Deviation 1.3
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
1-AG
|
10 picomoles per milliliter
Standard Deviation 12
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
2-AG
|
2.6 picomoles per milliliter
Standard Deviation 1.3
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
NO-Gly
|
0.25 picomoles per milliliter
Standard Deviation 0.26
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
NA-Gly
|
0.027 picomoles per milliliter
Standard Deviation 0.057
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
C14 Ceramide
|
0.49 picomoles per milliliter
Standard Deviation 0.28
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
C16 Ceramide
|
1.7 picomoles per milliliter
Standard Deviation 1.6
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
C18 Ceramide
|
0.34 picomoles per milliliter
Standard Deviation 0.32
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
C20 Ceramide
|
0.33 picomoles per milliliter
Standard Deviation 0.26
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
C24 Ceramide
|
0.41 picomoles per milliliter
Standard Deviation 0.28
|
|
Lower Back Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
18:1 Sphingosine
|
8.1 picomoles per milliliter
Standard Deviation 12
|
PRIMARY outcome
Timeframe: measured at study visit 2, detected lipid mediator concentrations reportedPopulation: Of the 14 subjects recruited for this study, only 4 provided usable data for this primary outcome.
Approximately 150 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids and endocannabinoid-like molecules, and sphingolipids.
Outcome measures
| Measure |
Single Group
n=4 Participants
All subjects will participate in 4 study day visits in the same order.
1. compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological induction of sweating (exercise using a stationary bicycle).
2. compare sweat collected following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) to upper surface of thigh (near the knee).
3. collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist).
4. collect blood and sweat samples before and 30 minutes, 2 hours and 4 hours after consumption of 400 mg of ibuprofen.
Ibuprofen: 400 mg ibuprofen given to inhibit COX metabolism
Physiological induction of sweating: 15 minutes exercise at 60-80% oxygen consumption to induce sweating
Pilocarpine: Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine
|
|---|---|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9-KODE
|
21 picomoles per milliliter
Standard Deviation 17
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
13-KODE
|
9.3 picomoles per milliliter
Standard Deviation 7.3
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
12,13-Ep-9-KODE
|
3.3 picomoles per milliliter
Standard Deviation 1.4
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
5-KETE
|
0.04 picomoles per milliliter
Standard Deviation 0.018
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
LTB5
|
0.088 picomoles per milliliter
Standard Deviation 0.068
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9-HODE
|
19 picomoles per milliliter
Standard Deviation 9.9
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
13-HODE
|
48 picomoles per milliliter
Standard Deviation 24
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9-HOTrE
|
1.8 picomoles per milliliter
Standard Deviation 0.54
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
13-HOTrE
|
5.2 picomoles per milliliter
Standard Deviation 1
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
5-HETE
|
0.067 picomoles per milliliter
Standard Deviation 0.059
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
8-HETE
|
0.17 picomoles per milliliter
Standard Deviation 0.066
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9-HETE
|
0.12 picomoles per milliliter
Standard Deviation 0.043
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
11-HETE
|
0.12 picomoles per milliliter
Standard Deviation 0.075
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
12-HETE
|
0.31 picomoles per milliliter
Standard Deviation 0.14
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
15-HETE
|
0.26 picomoles per milliliter
Standard Deviation 0.28
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
12-HEPE
|
0.13 picomoles per milliliter
Standard Deviation 0.057
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9,10-e-DiHO
|
35 picomoles per milliliter
Standard Deviation 5.5
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9,10-DiHOME
|
2.9 picomoles per milliliter
Standard Deviation 0.89
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
12,13-DiHOME
|
2.4 picomoles per milliliter
Standard Deviation 0.69
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9,10-DiHODE
|
0.46 picomoles per milliliter
Standard Deviation 0.095
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
12,13-DiHODE
|
0.7 picomoles per milliliter
Standard Deviation 0.13
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
15,16-DiHODE
|
0.99 picomoles per milliliter
Standard Deviation 0.31
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
5,6-DiHETrE
|
2.7 picomoles per milliliter
Standard Deviation 1.2
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
8,9-DiHETrE
|
0.62 picomoles per milliliter
Standard Deviation 0.45
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
11,12-DiHETrE
|
0.19 picomoles per milliliter
Standard Deviation 0.072
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
14,15-DiHETrE
|
0.19 picomoles per milliliter
Standard Deviation 0.087
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9,10-EpOME
|
1.7 picomoles per milliliter
Standard Deviation 0.54
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
12,13-EpOME
|
1.6 picomoles per milliliter
Standard Deviation 0.47
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
9,10-EpODE
|
0.8 picomoles per milliliter
Standard Deviation 0.66
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
12,13-EpODE
|
0.25 picomoles per milliliter
Standard Deviation 0.14
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
15,16-EpODE
|
0.95 picomoles per milliliter
Standard Deviation 0.45
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
10-Nitrooleate
|
0.12 picomoles per milliliter
Standard Deviation 0.14
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
10-Nitrolinoleate
|
0.16 picomoles per milliliter
Standard Deviation 0.019
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
PGE1
|
0.18 picomoles per milliliter
Standard Deviation 0.15
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
PGE2
|
0.36 picomoles per milliliter
Standard Deviation 0.38
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
PGF2a
|
0.44 picomoles per milliliter
Standard Deviation 0.45
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
PGE3
|
0.15 picomoles per milliliter
Standard Deviation 0.14
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
Sum TriHOMEs
|
36 picomoles per milliliter
Standard Deviation 14
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
PEA
|
18 picomoles per milliliter
Standard Deviation 6.4
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
SEA
|
18 picomoles per milliliter
Standard Deviation 5.8
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
OEA
|
0.31 picomoles per milliliter
Standard Deviation 0.24
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
LEA
|
0.078 picomoles per milliliter
Standard Deviation 0.039
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
aLEA
|
0.022 picomoles per milliliter
Standard Deviation 0.005
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
Dihomo GLA EA
|
0.00037 picomoles per milliliter
Standard Deviation 0.0058
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
AEA
|
0.013 picomoles per milliliter
Standard Deviation 0.005
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
DEA
|
0.053 picomoles per milliliter
Standard Deviation 0.061
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
1-OG
|
200 picomoles per milliliter
Standard Deviation 88
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
2-OG
|
37 picomoles per milliliter
Standard Deviation 16
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
1-LG
|
81 picomoles per milliliter
Standard Deviation 41
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
2-LG
|
2.1 picomoles per milliliter
Standard Deviation 0.6
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
1-AG
|
13 picomoles per milliliter
Standard Deviation 5.4
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
2-AG
|
4.2 picomoles per milliliter
Standard Deviation 0.72
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
NO-Gly
|
0.23 picomoles per milliliter
Standard Deviation 0.14
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
NA-Gly
|
0.02 picomoles per milliliter
Standard Deviation 0.013
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
C14 Ceramide
|
0.24 picomoles per milliliter
Standard Deviation 0.15
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
C16 Ceramide
|
1.5 picomoles per milliliter
Standard Deviation 1.2
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
C18 Ceramide
|
0.31 picomoles per milliliter
Standard Deviation 0.25
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
C20 Ceramide
|
0.36 picomoles per milliliter
Standard Deviation 0.32
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
C24 Ceramide
|
1 picomoles per milliliter
Standard Deviation 0.99
|
|
Anterior Distal Thigh Sweat Lipid Mediator Concentrations Following Pilocarpine Stimulation
18:1 Sphingosine
|
2.2 picomoles per milliliter
Standard Deviation 4.5
|
PRIMARY outcome
Timeframe: measured at four timepoints at study visit 4, detected lipid mediator concentrations for first timepoint reportedPopulation: Of the 14 subjects recruited for this study, only 9 provided usable data for this primary outcome.
Approximately 100 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids, and endocannabinoid-like molecules.
Outcome measures
| Measure |
Single Group
n=9 Participants
All subjects will participate in 4 study day visits in the same order.
1. compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological induction of sweating (exercise using a stationary bicycle).
2. compare sweat collected following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) to upper surface of thigh (near the knee).
3. collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist).
4. collect blood and sweat samples before and 30 minutes, 2 hours and 4 hours after consumption of 400 mg of ibuprofen.
Ibuprofen: 400 mg ibuprofen given to inhibit COX metabolism
Physiological induction of sweating: 15 minutes exercise at 60-80% oxygen consumption to induce sweating
Pilocarpine: Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine
|
|---|---|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
PGE1
|
0.126 picomoles per milliliter
Interval 0.04 to 0.421
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
PGE2
|
0.159 picomoles per milliliter
Interval 0.06 to 0.6
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
PGF2a
|
5.47 picomoles per milliliter
Interval 1.43 to 23.7
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
13-HODE
|
23 picomoles per milliliter
Interval 11.7 to 40.7
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
9-HODE
|
8.77 picomoles per milliliter
Interval 5.38 to 16.0
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
13-HOTE
|
1.56 picomoles per milliliter
Interval 0.92 to 4.65
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
9-HOTE
|
1.19 picomoles per milliliter
Interval 0.71 to 2.43
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
15-HETE
|
0.861 picomoles per milliliter
Interval 0.14 to 3.56
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
12-HETE
|
1.31 picomoles per milliliter
Interval 0.66 to 6.38
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
11-HETE
|
0.408 picomoles per milliliter
Interval 0.2 to 0.88
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
5-HETE
|
0.425 picomoles per milliliter
Interval 0.02 to 1.86
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
17-HDoHE
|
2.55 picomoles per milliliter
Interval 0.1 to 34.7
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
9,10-e-DiHO
|
10.4 picomoles per milliliter
Interval 5.76 to 34.1
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
12,13-DiHOME
|
4.13 picomoles per milliliter
Interval 2.24 to 10.4
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
9,10-DiHOME
|
4.44 picomoles per milliliter
Interval 1.44 to 12.0
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
15,16-DiHODE
|
15 picomoles per milliliter
Interval 6.96 to 37.5
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
12,13-DiHODE
|
1.77 picomoles per milliliter
Interval 0.3 to 7.52
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
9,10-DiHODE
|
0.458 picomoles per milliliter
Interval 0.2 to 1.04
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
14,15-DiHETrE
|
1.17 picomoles per milliliter
Interval 0.7 to 2.77
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
11,12-DiHETrE
|
1.11 picomoles per milliliter
Interval 0.56 to 3.09
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
5,6-DiHETrE
|
0.406 picomoles per milliliter
Interval 0.06 to 1.04
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
17,18-DiHETE
|
20.2 picomoles per milliliter
Interval 7.4 to 33.2
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
19,20-DiHDoPA
|
1.91 picomoles per milliliter
Interval 0.76 to 4.13
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
Sum TriHOMEs
|
7.88 picomoles per milliliter
Interval 4.64 to 12.2
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
9(10)-EpO
|
9.96 picomoles per milliliter
Interval 2.37 to 45.8
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
12(13)-EpOME
|
4.1 picomoles per milliliter
Interval 1.14 to 11.8
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
9(10)-EpOME
|
1.12 picomoles per milliliter
Interval 0.26 to 4.7
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
15(16)-EpODE
|
3.95 picomoles per milliliter
Interval 0.95 to 11.3
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
9(10)-EpODE
|
1.02 picomoles per milliliter
Interval 0.35 to 10.2
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
13-KODE
|
1.89 picomoles per milliliter
Interval 0.13 to 19.3
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
9-KODE
|
3.09 picomoles per milliliter
Interval 0.67 to 15.7
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
OEA
|
4.14 picomoles per milliliter
Interval 2.83 to 8.65
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
LEA
|
1.19 picomoles per milliliter
Interval 0.67 to 1.95
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
aLEA
|
0.0968 picomoles per milliliter
Interval 0.04 to 0.29
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
Dihomo GLA EA
|
0.168 picomoles per milliliter
Interval 0.05 to 0.39
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
AEA
|
0.627 picomoles per milliliter
Interval 0.29 to 0.92
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
DEA
|
0.298 picomoles per milliliter
Interval 0.21 to 0.48
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
DHEA
|
0.76 picomoles per milliliter
Interval 0.28 to 1.46
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
NO-Gly
|
3.5 picomoles per milliliter
Interval 1.62 to 9.44
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
NA-Gly
|
0.833 picomoles per milliliter
Interval 0.34 to 1.63
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
OG
|
393 picomoles per milliliter
Interval 212.0 to 702.0
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
LG
|
238 picomoles per milliliter
Interval 67.6 to 820.0
|
|
Change in Plasma Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
AG
|
20.7 picomoles per milliliter
Interval 10.0 to 51.2
|
SECONDARY outcome
Timeframe: measured at four timepoints at study visit 4, detected lipid mediator concentrations for first timepoint reportedPopulation: Of the 14 subjects recruited for this study, only 9 provided usable data for this primary outcome.
Approximately 100 lipid mediators will be measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Assayed lipid mediators include oxygenated lipids, endocannabinoids, and endocannabinoid-like molecules.
Outcome measures
| Measure |
Single Group
n=9 Participants
All subjects will participate in 4 study day visits in the same order.
1. compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological induction of sweating (exercise using a stationary bicycle).
2. compare sweat collected following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) to upper surface of thigh (near the knee).
3. collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist).
4. collect blood and sweat samples before and 30 minutes, 2 hours and 4 hours after consumption of 400 mg of ibuprofen.
Ibuprofen: 400 mg ibuprofen given to inhibit COX metabolism
Physiological induction of sweating: 15 minutes exercise at 60-80% oxygen consumption to induce sweating
Pilocarpine: Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine
|
|---|---|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
PGE1
|
0.453 picomoles per milliliter
Interval 0.12 to 4.91
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
PGE2
|
2.71 picomoles per milliliter
Interval 0.34 to 51.6
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
13-HODE
|
21.9 picomoles per milliliter
Interval 3.72 to 69.6
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
9-HODE
|
7.72 picomoles per milliliter
Interval 1.69 to 23.4
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
13-HOTE
|
1.08 picomoles per milliliter
Interval 0.29 to 3.23
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
9-HOTE
|
1.08 picomoles per milliliter
Interval 0.53 to 3.25
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
20-HETE
|
0.742 picomoles per milliliter
Interval 0.25 to 1.74
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
15-HETE
|
0.311 picomoles per milliliter
Interval 0.06 to 4.05
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
12-HETE
|
0.965 picomoles per milliliter
Interval 0.52 to 1.7
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
11-HETE
|
0.0882 picomoles per milliliter
Interval 0.01 to 0.39
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
8-HETE
|
0.0618 picomoles per milliliter
Interval 0.01 to 0.18
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
5-HETE
|
0.138 picomoles per milliliter
Interval 0.04 to 0.36
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
15-HEPE
|
0.0576 picomoles per milliliter
Interval 0.00136 to 0.3
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
12-HEPE
|
0.0781 picomoles per milliliter
Interval 0.01 to 0.23
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
17-HDoHE
|
0.46 picomoles per milliliter
Interval 0.09 to 7.41
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
9,10-e-DiHO
|
58.4 picomoles per milliliter
Interval 39.0 to 135.0
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
12,13-DiHOME
|
1.89 picomoles per milliliter
Interval 0.9 to 3.6
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
9,10-DiHOME
|
3.61 picomoles per milliliter
Interval 1.85 to 7.66
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
15,16-DiHODE
|
1.49 picomoles per milliliter
Interval 0.43 to 5.65
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
12,13-DiHODE
|
0.332 picomoles per milliliter
Interval 0.12 to 1.34
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
9,10-DiHODE
|
0.35 picomoles per milliliter
Interval 0.1 to 0.87
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
14,15-DiHETrE
|
0.341 picomoles per milliliter
Interval 0.09 to 1.09
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
11,12-DiHETrE
|
0.231 picomoles per milliliter
Interval 0.07 to 1.02
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
5,6-DiHETrE
|
3.29 picomoles per milliliter
Interval 1.28 to 10.7
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
17,18-DiHETE
|
1.76 picomoles per milliliter
Interval 0.31 to 6.72
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
Sum TriHOMEs
|
31.7 picomoles per milliliter
Interval 11.4 to 93.5
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
9(10)-EpO
|
2.81 picomoles per milliliter
Interval 0.89 to 6.54
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
12(13)-EpOME
|
0.485 picomoles per milliliter
Interval 0.08 to 1.31
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
9(10)-EpOME
|
0.657 picomoles per milliliter
Interval 0.16 to 1.93
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
15(16)-EpODE
|
0.491 picomoles per milliliter
Interval 0.04 to 4.5
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
12(13)-EpODE
|
0.0703 picomoles per milliliter
Interval 0.02 to 0.14
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
9(10)-EpODE
|
0.194 picomoles per milliliter
Interval 0.04 to 0.51
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
13-KODE
|
2.17 picomoles per milliliter
Interval 0.3 to 13.2
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
9-KODE
|
5.35 picomoles per milliliter
Interval 0.64 to 38.5
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
12(13)-Ep-9-KODE
|
1.82 picomoles per milliliter
Interval 0.72 to 3.64
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
10-Nitrooleate
|
1.78 picomoles per milliliter
Interval 0.36 to 6.24
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
9-Nitrooleate
|
0.729 picomoles per milliliter
Interval 0.09 to 3.76
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
10-Nitrolinoleate
|
0.297 picomoles per milliliter
Interval 0.16 to 0.6
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
OEA
|
0.586 picomoles per milliliter
Interval 0.09 to 2.7
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
LEA
|
0.0447 picomoles per milliliter
Interval 0.01 to 0.22
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
NO-Gly
|
0.156 picomoles per milliliter
Interval 0.01 to 0.55
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
NA-Gly
|
0.0627 picomoles per milliliter
Interval 0.01 to 0.23
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
OG
|
61.5 picomoles per milliliter
Interval 2.67 to 5620.0
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
LG
|
4.11 picomoles per milliliter
Interval 0.46 to 21.2
|
|
Change in Pilocarpine-stimulated Sweat Lipid Mediator Concentrations Before and After Oral Ibuprofen Administration
AG
|
4.2 picomoles per milliliter
Interval 0.15 to 836.0
|
SECONDARY outcome
Timeframe: measured at four timepoints at study visit 4Population: Of the 14 subjects recruited for this study, only 9 provided usable data for this primary outcome.
Plasma concentration of ibuprofen prior to and 30 min, 2 hr and 4 hr after oral administration
Outcome measures
| Measure |
Single Group
n=9 Participants
All subjects will participate in 4 study day visits in the same order.
1. compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological induction of sweating (exercise using a stationary bicycle).
2. compare sweat collected following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) to upper surface of thigh (near the knee).
3. collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist).
4. collect blood and sweat samples before and 30 minutes, 2 hours and 4 hours after consumption of 400 mg of ibuprofen.
Ibuprofen: 400 mg ibuprofen given to inhibit COX metabolism
Physiological induction of sweating: 15 minutes exercise at 60-80% oxygen consumption to induce sweating
Pilocarpine: Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine
|
|---|---|
|
Change in Plasma Ibuprofen Concentrations
Prior to administration
|
0 micrograms per milliliter
Interval 0.0 to 0.0
|
|
Change in Plasma Ibuprofen Concentrations
30 min after administration
|
18.8 micrograms per milliliter
Interval 3.4 to 65.3
|
|
Change in Plasma Ibuprofen Concentrations
2 hr after administration
|
48.3 micrograms per milliliter
Interval 39.1 to 75.9
|
|
Change in Plasma Ibuprofen Concentrations
4 hr after administration
|
33.8 micrograms per milliliter
Interval 14.9 to 90.1
|
SECONDARY outcome
Timeframe: measured at four timepoints at study visit 4Population: Of the 14 subjects recruited for this study, only 9 provided usable data for this primary outcome.
Sweat concentration of ibuprofen prior to and 30 min, 2 hr and 4 hr after oral administration
Outcome measures
| Measure |
Single Group
n=9 Participants
All subjects will participate in 4 study day visits in the same order.
1. compare sweat collected following pharmacological stimulation of sweating (using the drug pilocarpine) to sweat collected following physiological induction of sweating (exercise using a stationary bicycle).
2. compare sweat collected following stimulation of sweating by the drug pilocarpine from the inner part of the forearm (near the wrist) to upper surface of thigh (near the knee).
3. collect sweat following stimulation of sweating by the drug pilocarpine from the inner part of both forearms (near the wrist).
4. collect blood and sweat samples before and 30 minutes, 2 hours and 4 hours after consumption of 400 mg of ibuprofen.
Ibuprofen: 400 mg ibuprofen given to inhibit COX metabolism
Physiological induction of sweating: 15 minutes exercise at 60-80% oxygen consumption to induce sweating
Pilocarpine: Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine
|
|---|---|
|
Change in Sweat Ibuprofen Concentrations
Prior to administration
|
0 micrograms per milliliter
Interval 0.0 to 0.0
|
|
Change in Sweat Ibuprofen Concentrations
30 min after administration
|
0 micrograms per milliliter
Interval 0.0 to 0.0
|
|
Change in Sweat Ibuprofen Concentrations
2 hr after administration
|
0 micrograms per milliliter
Interval 0.0 to 0.0
|
|
Change in Sweat Ibuprofen Concentrations
4 hr after administration
|
0 micrograms per milliliter
Interval 0.0 to 0.0
|
Adverse Events
Single Group
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Dr. John W. Newman
USDA, ARS Western Human Nutrition Research Center
Phone: 530-752-1009
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place